CMS Cuts Threaten Diabetes Device Margins, Here’s How AI Can Turn the Tide

The Centers for Medicare & Medicaid Services (CMS) recently proposed a sweeping 6.4% reduction to the Home Health Prospective Payment System (HH PPS) for Calendar Year 2026. While headlines have focused on the home-health industry’s reaction—closures, consolidation, and care deserts—there’s an under-examined but highly material ripple effect taking shape in the diabetes technology sector.

For manufacturers of Continuous Glucose Monitors (CGMs) and insulin pumps, this isn’t just a policy adjustment. It’s a structural disruption to a key commercial channel, with implications for margin stability, go-to-market architecture, and long-term reimbursement positioning.

The Overlooked Role of Home Health in Diabetes Tech

Home-health services play a pivotal, if often invisible, role in diabetes device adoption. Across Medicare and commercial populations alike, CGMs and insulin pumps are frequently delivered and initialised by home-health agencies. Nurses provide in-home setup, training, calibration, and adherence monitoring—particularly for elderly, disabled, or poly-morbid patients.

This high-touch model helps optimise clinical outcomes and reduce readmissions, while supporting premium pricing by embedding the device within a broader care continuum.

Until now, that model has offered mutual reinforcement: better outcomes for patients, stronger reimbursement for providers, and higher margin realisation for manufacturers. But with CMS now proposing over $1.1 billion in cuts—including a -4.059% permanent adjustment and a -5% “clawback” for previous overpayments—that alignment is under threat.